A US-based KOL covers treatment methodologies pathways for MDS patients at different risk levels. This interview also covers available treatment options for patients with lower- and higher-risk MDS, pipeline therapies and the potential for checkpoint inhibitor use in MDS.

This interview was conducted on 05 September, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.